Our Mission
The ACC Nevada Chapter is dedicated to advancing the field of cardiovascular care through innovation, advocacy, and professional development, ensuring that Nevada’s clinicians are equipped to meet the evolving health challenges of our state.
|
ACC Live Courses For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings |
Please join your cardiology colleagues at the ACC Rockies Chapter Meeting in Park City, Utah for updates on ACC affairs, the potential new CV Board, and clinical topics such as Genetic and Sports EP, plus a discussion on the growing role of obesity medications in heart failure, and the first-ever Cardiology State-of-the-State report. There will be many opportunities for networking, as well!.
For more information and to register, please visit: 
Latest in Cardiology from ACC.org
- CAPLA: Long-Term QOL Improvement With CA For Persistent AFibQuality of life (QOL) at three years significantly improved following catheter ablation (CA) for persistent atrial fibrillation (PsAFib), according to a secondary analysis of patients in the CAPLA clinical trial published in JACC: Clinical Electrophysiology.
- Thrombotic Events In ATTR-CM Patients Linked to Primary LA CardiopathyPrimary left atrial (LA) cardiopathy appears to be linked to the high risk of thrombotic events (TE) in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) independent of atrial fibrillation (AFib), CHA2DS2-VASc score and LA dilatation. This link differs from patients with other left ventricular hypertrophy (LVH) phenotypes according to a new study published in JACC: Cardiovascular […]
- REDEFINE 1 and REDEFINE 2: Greater Weight Loss With Combined Cagrilintide-Semaglutide vs. Either Drug Alone or PlaceboThe combination of cagrilintide with semaglutide (CagriSema) in a single weekly injection was associated with a significantly greater weight loss in adults with overweight or obesity regardless of type 2 diabetes (T2D) status compared with placebo or either drug alone...
- Starting DOACs Early After Stroke Lowers Risk of Future Strokes, HemorrhageInitiating direct oral anticoagulants (DOACs) within four days, rather than at five days or later, after an ischemic stroke in patients with atrial fibrillation (AFib) reduced the risk of future stroke events within 30 days without increasing symptomatic intracerebral hemorrhage...
- Poll: Transcatheter Mitral Valve Replacement in a High Surgical Risk Patient With Mitral StenosisMrs. M is an 81-year-old female patient who presents with worsening exertional dyspnea. She has a history of type 2 diabetes mellitus, heart failure with preserved ejection fraction, and prior surgical aortic valve replacement in the setting of severe symptomatic aortic stenosis.